FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection
Created by News on 12/14/2008 10:47:01 PM

Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.


WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

In the approval, the FDA required that LUSEDRA be used only by persons trained in the administration of general anesthesia and that all patients should be continuously monitored by persons not involved in the conduct of the procedure.

On May 7, 2008, the FDA Advisory Committee on Anesthetic and Life Support Drugs voted 6 to 3 in favor (with one abstention) of approval of LUSEDRA for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures. The committee recommended use of LUSEDRA by healthcare providers who are appropriately trained.

"We are pleased with the FDA's decision to approve Lusedra, as it provides a new option for monitored anesthesia care (MAC) sedation in adult patients," said Cynthia Schwalm, President, Eisai Inc. "With the approval of Lusedra, Eisai continues to fulfill its human health care mission to address the unmet needs of patients."

The FDA has recommended that LUSEDRA be classified as a controlled substance. A final scheduling decision is expected from the U.S. Drug Enforcement Administration (DEA) after publishing a proposed rule in the Federal Register and allowing for public comment. Once LUSEDRA receives final scheduling designation, the label will be amended.

About LUSEDRA(TM) (fospropofol disodium) Injection

LUSEDRA(TM) (fospropofol disodium) Injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by alkaline phosphatase enzymes in the body into propofol. LUSEDRA is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

Important Safety Information

LUSEDRA should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the diagnostic or therapeutic procedure. Patients should be continuously monitored during sedation and through the recovery process for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. Facilities for providing cardiopulmonary resuscitation must be immediately available.

The following serious adverse reactions have been reported with the use of LUSEDRA.

-- Hypotension
       -- Hypotension was reported in 18/455 (4%) patients treated with
          LUSEDRA using the standard or modified dosing regimen.
       -- Patients with compromised myocardial function, reduced vascular
          tone, or who have reduced intravascular volume may be at an
          increased risk for hypotension.

    -- Hypoxemia
       -- Hypoxemia was reported in 20/455 (4%) patients treated with LUSEDRA
          using the standard or modified dosing regimen. Retention of
          purposeful responsiveness did not prevent patients from becoming
          hypoxemic following administration of LUSEDRA.

    -- Respiratory depression
       -- Apnea was reported in 1/455 (< 1%) patients treated with LUSEDRA
          using the standard or modified dosing regimen.

    -- Loss of purposeful responsiveness
       -- LUSEDRA has not been studied for use in general anesthesia. However,
          administration of LUSEDRA may inadvertently cause patients to become
          unresponsive or minimally responsive to vigorous tactile or painful
          stimulation. The incidence of patients who became minimally
          responsive or unresponsive to vigorous tactile or painful
          stimulation was 7/183 (4%) for colonoscopy and 24/149 (16%) for
          bronchoscopy. The duration of minimal or complete unresponsiveness
          ranged from 2 to 16 minutes in colonoscopy patients and from 2 to 20
          minutes in bronchoscopy patients.

The use of supplemental oxygen is recommended in all patients receiving LUSEDRA. Airway assistance maneuvers may be required. As with other sedative-hypnotic agents, LUSEDRA may produce additive cardio-respiratory effects when administered with other cardio-respiratory depressants such as benzodiazepines and narcotic analgesics. When LUSEDRA is used at greater than the recommended doses, the incidence of serious adverse reactions is increased.

The most common adverse reactions (reported in greater than 20%) are paresthesia and pruritis.

Please see FDA-approved labeling text at
http://www.eisai.com/presskit.asp?ID=217 .

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit www.eisai.com.

About Eisai Inc.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. that was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of MGI PHARMA, Inc.

Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC,

and in the field. For more information about Eisai, please visit www.eisai.com.

 

print
The comment feature is locked by administrator.
Search News
Top Stories

Apr24 Dental Health Products, Inc. (DHPI) Announces Strategic Alliance with the Dental Exchange
Created by Admin on 4/24/2015 9:24:38 AM

 Dental Health Products, Inc. (DHPI) and The Dental Exchange have announced the formation of a ne...
Read More..

Mar12 Dr. Richard Hughes Named an Honored Fellow of the American Academy of Implant Dentistry
Created by udent webmaster on 3/12/2015 11:04:13 AM

The American Academy of Implant Dentistry (AAID) has named Dr. Richard Hughes an Honored Fellow due ...
Read More..

Mar12 Deerfield Delivers Superior Veterinary Dentistry with Elite Drill
Created by udent webmaster on 3/12/2015 10:41:57 AM

One of Springfield’s leading animal hospitals continues its commitment to providing the best in vete...
Read More..

Mar12 Studio B Dental Launches New Website Specifically for Their All on 4 Dental Implant Procedure
Created by udent webmaster on 3/12/2015 10:39:47 AM

The new website launched by the popular Toronto dental clinic offers a simple 2 minute assessment fo...
Read More..

Mar09 Dr. E. Dale Behner Gives Indianapolis, IN Residents Access to a Minimally Invasive Receding Gums Treatment
Created by udent webmaster on 3/9/2015 10:09:50 PM

Dr. E. Dale Behner of Dental Care Today, PC is expanding his practice to offer help to those with re...
Read More..

Mar09 Growing Emphasis on Prevention of Caries Drives the Global Dental Preventive Supplies Market, According to a New Report by Global Industry Analysts, Inc
Created by udent webmaster on 3/9/2015 10:06:00 PM

Dental caries or tooth decay is one of the major issues for public healthcare systems in most countr...
Read More..

Mar07 Dr. John Schiro DDS Opens New Cosmetic Dentistry Practice in Austin, Texas
Created by udent webmaster on 3/7/2015 4:10:59 PM

Dr. John Schiro DDS is now announcing the grand opening of his new cosmetic dentistry practice in A...
Read More..

Mar20 One Third of Americans Still in Need of Affordable Dental Care Options
Created by Melissa Watkins on 3/20/2014 11:46:00 AM

According to Healthcare.gov, the Health and Human Services arm that is in charge of the federal heal...
Read More..

Feb11 DENTALPLANS.COM CREATES ONLINE PROJECT CENTER FOR NATIONAL CHILDREN’S DENTAL HEALTH MONTH
Created by Melissa Watkins on 2/11/2014 12:50:00 PM

 etting children to brush and floss every day isn’t always easy, especially when parents have a mil...
Read More..

Feb10 126.7 MILLION AMERICANS IN NEED OF DENTAL CARE OPTIONS
Created by Melissa Watkins on 2/10/2014 11:13:00 AM

 As the Affordable Care Act (ACA) discussion switches from accessing the federal and state health e...
Read More..

Jan21 DENTALPLANS.COM APPOINTS BOB HARRIS CHIEF EXECUTIVE OFFICER
Created by Melissa Watkins on 1/21/2014 3:39:00 PM

 entalPlans.com, a leading provider of dental savings plans, has named Bob Harris as chief executiv...
Read More..

Oct16 Keep Your Teeth White !
Created by Mint Cosmetics Review on 10/16/2013 11:58:00 PM

Great plastic is a teeth bleaching package which is prescribed by simply the majority of the dental ...
Read More..

Aug01 Gummy Smiles: What Are My Treatment Options?
Created by mapleavenuefamilydentistry on 8/1/2013 6:29:00 AM

When most people smile, you see a row of teeth that look beautiful and full. Unfortunately, this is ...
Read More..

Jul27 Plastic Surgeons Nj – A Smart Gateway To Beautification
Created by Dr. Michael A. Fiorillo, MD on 7/27/2013 12:05:00 AM

Plastic Surgeons Nj are veterans in the field of plastic surgery. These surgeons can completely cha...
Read More..

Jul22 Dental Implants: Evidence of Modern Dentistry
Created by paul589649 on 7/22/2013 4:50:00 AM

You can find out more about -   Dentist West Hartford CT , Dental Implants West Haven CT , De...
Read More..

Oct22 Guidance of Taking Good Care Of Braces
Created by bonniemendes on 10/22/2012 11:50:00 PM

 Guidance of Taking Good Care Of Braces Finding dependable techniques for taking care of braces as ...
Read More..

Aug13 Periodontist Comments On New Study Examining Diabetes Drug That May Be Able To Fight Oral Cancer
Created by Dr. Alex Farnoosh on 8/13/2012 12:24:00 PM

About The Total Smile: The Total Smile was founded by Beverly Hills Periodontist Dr. Alex Farn...
Read More..

Jul17 360imaging releases an improved version 4 of 360DPS dental implant planning software
Created by Manal on 7/17/2012 4:25:00 AM

 360 Imaging – an industry leader in dental implant planning - recently announced the release of  v...
Read More..

Jul11 iCare Financial Launches Strategic Alliance With Concorde Communications To Benefit Growth Of Dental Practices
Created by iCare Credit on 7/11/2012 4:28:00 PM

iCare Financial, a leading provider of patient credit, and Concorde Communications, an acclaimed me...
Read More..

Jun26 Periodontist Discusses Study Linking Osteoporosis Drug Complications To Patients With Certain Genes
Created by Dr. Alex Farnoosh on 6/26/2012 10:14:00 AM

On the heels of an earlier study linking antiresorptive drugs to medication induced osteonecrosis...
Read More..